Content about Sweden

December 27, 2012
Study: Stroke survivors lacking antioxidant carotenoids in their gut flora

Researchers at the University of Gothenburg along with the Chalmers University of Technology earlier this month demonstrated that an altered gut microbiota in humans is associated with symptomatic atherosclerosis and stroke.

GOTHENBURG, Sweden — Researchers at the University of Gothenburg along with the Chalmers University of Technology earlier this month demonstrated that an altered gut microbiota in humans is associated with symptomatic atherosclerosis and stroke. 

These findings were presented in a study published in Nature Communications on Dec. 4.

December 7, 2012
Meda expands OTC portfolio with MidNite sleep aid acquisition

Meda announced Friday that it has signed an agreement to acquire MidNite, an OTC sleep-aid product.

SOLNA, Sweden — Meda announced Friday that it has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Transaction terms were not disclosed.

“This acquisition enhances our presence in the U.S. ahead of other future OTC launches," stated Anders Lönner, CEO of Meda. 

Annualized revenues for MidNite are approximately $15 million, the company reported. 

March 1, 2011
Cold sore treatment Xerese enters market

Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.

HUDDINGE, Sweden — Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.

The Swedish drug maker launched Xerese (acyclovir and hydrocortisone), a topical combination product designed to treat recurrent herpes simplex labialis.

Medivir said the U.S. market for cold sore products is $230 million, and it expected the drug to be successful, given Meda’s presence in the U.S. market.

January 10, 2011
Boots Pharmaceutical Enterprises gears up to open pharmacies across Sweden

Boots Pharmaceutical Enterprises, the partnership between the U.K. pharmacy chain Boots and local operator Pharmaceutical Enterprises, in the next two months is expected to open the first of 100 pharmacies across Sweden, according to a report in The Local, an English-language Swedish newspaper.

STOCKHOLM, Sweden — Boots Pharmaceutical Enterprises, the partnership between the U.K. pharmacy chain Boots and local operator Pharmaceutical Enterprises, in the next two months is expected to open the first of 100 pharmacies across Sweden, according to a report in The Local, an English-language Swedish newspaper.

”We are busy recruiting candidates and finding premises here in Sweden,” Sverker Littorin, Pharmaceutical Enterprises chairman told the newspaper. “Everything is on track, even though it is several months later than we had hoped.”

September 19, 2010
Sanofi-Aventis: Lantus provides further blood-sugar reduction for patients with Type 2 diabetes

An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar...

PARIS An injected insulin made by French drug maker Sanofi-Aventis provided further reduction of blood sugar in patients with Type 2 diabetes when added to oral diabetes drugs, according to a study presented at a medical conference in Sweden.